Edwards Lifesciences/$EW
1D1W1MYTD1Y5YMAX
Capital at risk
About Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
- Ticker
- $EW
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 16,000
- Headquarters
- Irvine, United States
- Website
- www.edwards.com
EW Metrics
BasicAdvanced
$51B
51.34
$1.72
0.85
-
Price and volume
Market cap
$51B
Beta
0.85
52-week high
$96.29
52-week low
$72.30
Average daily volume
3M
Financial strength
Current ratio
4.522
Quick ratio
3.454
Long term debt to equity
0.063
Total debt to equity
0.068
Interest coverage (TTM)
89.77%
Profitability
EBITDA (TTM)
1,995
Gross margin (TTM)
77.84%
Net profit margin (TTM)
15.43%
Operating margin (TTM)
28.12%
Effective tax rate (TTM)
30.97%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
8.37%
Return on equity (TTM)
9.18%
Valuation
Price to earnings (TTM)
51.341
Price to revenue (TTM)
7.864
Price to book
4.79
Price to tangible book (TTM)
7
Price to free cash flow (TTM)
35.723
Free cash flow yield (TTM)
2.80%
Free cash flow per share (TTM)
2.471
Growth
Revenue change (TTM)
14.55%
Earnings per share change (TTM)
-75.50%
3-year revenue growth (CAGR)
8.02%
10-year revenue growth (CAGR)
9.03%
3-year earnings per share growth (CAGR)
-8.78%
10-year earnings per share growth (CAGR)
7.86%
What the Analysts think about EW
Analyst ratings (Buy, Hold, Sell) for Edwards Lifesciences stock.
Analyst projections of the future price of Edwards Lifesciences stock.
Bulls say / Bears say
Edwards delivered strong second-quarter execution, with sales up 13.6% and adjusted EPS of $0.78. Management raised 2026 total-company constant-currency sales growth guidance to 10% to 11% and maintained adjusted EPS growth of about 17% at the midpoint. (Edwards Lifesciences)
The mitral and tricuspid business is scaling quickly and could diversify Edwards beyond TAVR. Second-quarter TMTT sales rose 47.3% to $195.9 million, while planned PASCAL, SAPIEN M3 and EVOQUE launches and approvals provide further growth avenues. (Edwards Lifesciences)
CMS has updated its TAVR coverage policy to improve patient access and give Heart Teams more flexibility in treatment decisions. The change should enlarge the addressable patient pool over time, although the benefit is likely to build gradually as hospitals implement it. (Edwards Lifesciences, Zenopa)
TAVR remains Edwards’ largest product group, but management now expects 2026 TAVR growth of 8% to 9%, below total-company growth of 10% to 11%. This suggests the core franchise is becoming a steadier, more mature growth engine. (Edwards Lifesciences)
Tax pressure is reducing the benefit of strong operating growth. Edwards expects its 2026 effective tax rate to be at the high end of 16% to 19% because of Pillar Two rules and tighter limits on California R&D credits. (Edwards Lifesciences)
Valuation leaves limited room for disappointment. A recent analysis found that EW traded at a 75% premium to the medical-equipment sector median and estimated only about 4% upside in its probability-weighted valuation. (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
EW Financial Performance
Revenues and expenses
EW Earnings Performance
Company profitability
Upcoming events
No upcoming events
EW News
AllArticlesVideos
Funds containing EW
AllEURUSDGBP
Fund name | Fund size | $EW weighting |
|---|---|---|
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 1.29% |
iShares Healthcare Innovation$HEAL | $1.4B | 1.24% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.24% |
iShares Healthcare Innovation£DRDR | £1B | 1.24% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.83% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.